Sofosbuvir/Velpatasvir/Voxilaprevir Experience in Treatment-Naive Chronic Hepatitis C Patients: Preliminary Findings of Real World Data

Basit Öğe Kaydı
dc.contributor.authorCakirca, Tuba Damar
dc.contributor.authorYamazhan, Tansu
dc.contributor.authorYuksekkaya, Esra
dc.contributor.authorAkgul, Fethiye
dc.contributor.authorKurtaran, Behice
dc.contributor.authorKarasahin, Omer
dc.contributor.authorKarabay, Oguz
dc.date.accessioned2024-04-24T17:24:33Z
dc.date.available2024-04-24T17:24:33Z
dc.date.issued2023
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: The aim of this study was to present the preliminary findings of real-world data of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in treatment-naive chronic hepatitis C (CHC) patients, which was approved for the first time in treatment-naive patients in Turkey. Materials and Methods: This retrospective, cross-sectional, multicenter and national study comprised treatment-naive CHC patients receiving SOF/VEL/VOX between June-December 2022 in ten centers from Turkey. The sustained virological response (SVR) was defined as undetectable hepatitis C virus (HCV)-RNA after at least 12 weeks or more from the end of antiviral therapy. Results: Forty one patients initiating SOF/VEL/VOX were included in the study; median age 55 [interquartile range (IQR): 34.5-61 years], 63.4% males, and median HCV-RNA 521,644 IU/mL. Genotype distribution ranged from 1 to 4 in 28 patients who underwent genotype analysis, and genotype-1 was detected in 24 (85.7%) patients. The most common risk factor was substance abuse (n=10, 24.4%) and the most common comorbidity was hypertension (n=111, 26.8%). 3 (7.3%) patients had compensated cirrhosis and one (2.4%) had hepatocellular carcinoma. While in the 1st month of treatment, HCV-RNA was negative in all patients except one patient, at the end of treatment all patients' viral load was negative. SVR12 results were available in 23 patients and SVR24 in 10 patients. SVR12 and SVR24 were achieved in all patients who could be evaluated (100%) (SVR12, 23/23; SVR24, 10/10). Adverse events were reported by two patients: Diarrhea (2.4%) and nausea (2.4%), but did not lead to a discontinuation of treatment. Conclusion: The preliminary results of our study corroborated the efficacy and well tolerateability of SOF/VEL/VOX in treatment- naive CHC patients. High SVR rates were also observed across genotypes 1, 2, 3, 4 with the pangenotypic SOF/VEL/VOX.en_US
dc.identifier.doi10.4274/vhd.galenos.2023.2023-5-2
dc.identifier.endpage63en_US
dc.identifier.issn1307-9441
dc.identifier.issn2147-2939
dc.identifier.issue2en_US
dc.identifier.startpage58en_US
dc.identifier.urihttps://doi.org/10.4274/vhd.galenos.2023.2023-5-2
dc.identifier.urihttps://hdl.handle.net/11468/19730
dc.identifier.volume29en_US
dc.identifier.wosWOS:001080086800004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofViral Hepatit Dergisi-Viral Hepatitis Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis C Treatmenten_US
dc.subjectSofosbuvir/Velpatasvir/ Voxilapreviren_US
dc.subjectReal-World Dataen_US
dc.subjectDirect Acting Antiviralsen_US
dc.titleSofosbuvir/Velpatasvir/Voxilaprevir Experience in Treatment-Naive Chronic Hepatitis C Patients: Preliminary Findings of Real World Dataen_US
dc.titleSofosbuvir/Velpatasvir/Voxilaprevir Experience in Treatment-Naive Chronic Hepatitis C Patients: Preliminary Findings of Real World Data
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu